Generic placeholder image

Current Protein & Peptide Science

Editor-in-Chief

ISSN (Print): 1389-2037
ISSN (Online): 1875-5550

Review Article

Recent Updates on Molecular Genetic Engineering Approaches and Applications of Human Therapeutic Proteins

Author(s): Asim Azhar, Ejaj Ahmad, Qamar Zia, Mohammad Owais and Ghulam Md Ashraf

Volume 18, Issue 3, 2017

Page: [217 - 232] Pages: 16

DOI: 10.2174/1389203717666160901114911

Price: $65

Abstract

Therapeutic proteins are engineered proteins produced in the laboratory for pharmaceutical use. With the advent of recombinant DNA technology, the proteins can be generated in specific host cells under defined conditions. In the process of production of genetically engineered animals, the gene of interest can be added at a single cell stage to produce a cloned animal from genetically engineered cells. Several recombinant cytokines, clotting factors etc have been licensed and are currently being utilized for the treatment of cancer, infectious diseases, hemophilia, anemia, multiple sclerosis, and hepatitis B/C. Therapeutic proteins that are useful for human are successfully produced in poultry as well as in livestock animals. However, the fastest growing class of therapeutic proteins are antibodies especially monoclonal antibodies (mAb), the most important class of therapeutic protein with the potential to generate significant revolution in terms of clinical success rate. Here, we review the most recent clinical advances in the field of emerging and existing therapeutic proteins.

Keywords: Chimeric antibodies, clotting factors, cytokines, hormones, medicinal chemistry, therapeutic proteins.

Graphical Abstract


Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy